XENON PHARMACEUTICALS
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1996-01-01
- Employees
- -
- Market Cap
- $3.1B
- Website
- http://www.xenon-pharma.com/
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT03796962
- Locations
- 🇺🇸
James W. Aston Ambulatory Care Center, Dallas, Texas, United States
🇺🇸Don Clinical Research Center, Miami, Florida, United States
🇺🇸The Neurology Research Group, LLC., Miami, Florida, United States
Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101
Phase 1
Completed
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03468725
- Locations
- 🇬🇧
King's College Hospital, Brixton, London, United Kingdom
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Inert Ingredients Oral Product
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03467100
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, United Kingdom
Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT03340220
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., London, United Kingdom
A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT02656043
- Locations
- 🇨🇦
Lynderm Research Inc, Markham, Ontario, Canada
🇨🇦Toole Dermatology Research, Winnipeg, Manitoba, Canada
🇨🇦Windsor Clinical Research Inc., Windsor, Ontario, Canada
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Phase 1
Completed
- Conditions
- Inherited ErythromelalgiaPrimary Erythromelalgia
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01486446
- Locations
- 🇺🇸
Pinnacle Research Group, LLC., Anniston, Alabama, United States
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT01195636
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
Phase 1
Completed
- Conditions
- Primary ErythromelalgiaInherited Erythromelalgia
- Interventions
- Drug: PlaceboDrug: XPF-001
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2012-03-16
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT01090622
- Locations
- 🇳🇱
Clinical Research Centre at Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction
Phase 2
Completed
- Conditions
- Dental Pain
- Interventions
- Drug: placeboDrug: XPF-001
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00954356
- Locations
- 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States
Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Human Volunteers
- Interventions
- Drug: XPF-001
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00813670
- Locations
- 🇨🇦
Anapharm, Montreal, Quebec, Canada
© Copyright 2025. All Rights Reserved by MedPath